Publications by authors named "Gunnar Fager"

Claim this Profile
P
PC-Based ECG waveform recognition-validation of novel software against a reference ECG database.
Corina-Dana Dota, Nils Edvardsson, Bo Skallefell, Gunnar Fager

Ann Noninvasive Electrocardiol· January 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prevention of clot formation during haemodialysis using the direct thrombin inhibitor melagatran in patients with chronic uraemia.
Per-Ola Attman, Pia Ottosson, Ola Samuelsson, Ulf G Eriksson, Maria Eriksson-Lepkowska, Gunnar Fager

Nephrol Dial Transplant· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Characterisation and application of antibodies specific for the long platelet-derived growth factor A and B chains.
Gunnel Ostergren-Lundén, Raquel G Olivas, Pierre Eftekhari, Alexandra Krettek, Xavier Sanjuan, Gunnar Fager

Int J Biochem Cell Biol· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of severe renal impairment on the pharmacokinetics and pharmacodynamics of oral ximelagatran and subcutaneous melagatran.
Ulf G Eriksson, Susanne Johansson, Per-Ola Attman, Henrik Mulec, Lars Frison, Gunnar Fager

Clin Pharmacokinet· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
No influence of mild-to-moderate hepatic impairment on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
Karin Wåhlander, Maria Eriksson-Lepkowska, Lars Frison, Gunnar Fager, Ulf G Eriksson

Clin Pharmacokinet· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential binding of platelet-derived growth factor isoforms to glycosaminoglycans.
Raquel García-Olivas, Johan Hoebeke, Susanna Castel, Manuel Reina, Gunnar Fager

Histochem Cell Biol· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
No influence of ethnic origin on the pharmacokinetics and pharmacodynamics of melagatran following oral administration of ximelagatran, a novel oral direct thrombin inhibitor, to healthy male volunteers.
Linda C Johansson, Magnus Andersson, Gunnar Fager, David Gustafsson, Ulf G Eriksson

Clin Pharmacokinet· September 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of melagatran, the active form of the oral direct thrombin inhibitor ximelagatran, are not influenced by acetylsalicylic acid.
Gunnar Fager, Marie Cullberg, Maria Eriksson-Lepkowska, Lars Frison, Ulf G Eriksson

Eur J Clin Pharmacol· August 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor.
Linda C Johansson, Lars Frison, Ulrika Logren, Gunnar Fager, David Gustafsson

Clin Pharmacokinet· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans.
Ulf G Eriksson, Ulf Bredberg, Kurt-Jürgen Hoffmann, Anneli Thuresson, Margareth Gabrielsson, Gunnar Fager

Drug Metab Dispos· March 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of ximelagatran, an oral direct thrombin inhibitor, r-hirudin and enoxaparin on thrombin generation and platelet activation in healthy male subjects.
Troy C Sarich, Michael Wolzt, Ulf G Eriksson, Christer Mattsson, Alice Schmidt, Gunnar Fager

J Am Coll Cardiol· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inter- and intraday variability in major electrocardiogram intervals and amplitudes in healthy men and women.
Corina D Dota, Nils Edvardsson, Kajs-Marie Schützer, Eva Lavik Olofsson, Anders Malm, Gunnar Fager

Pacing Clin Electrophysiol· January 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Computer-based analysis of dynamic QT changes: toward high precision and individual rate correction.
Corina Dota, Bo Skallefell, Nils Edvardsson, Gunnar Fager

Ann Noninvasive Electrocardiol· October 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A dose-ranging study of the oral direct thrombin inhibitor, ximelagatran, and its subcutaneous form, melagatran, compared with dalteparin in the prophylaxis of thromboembolism after hip or knee replacement: METHRO I. MElagatran for THRombin inhibition in Orthopaedic surgery.
Bengt I Eriksson, Ann-Christin Arfwidsson, Lars Frison, Ulf G Eriksson, Anders Bylock, Gunnar Fager

Thromb Haemost· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of thrombin generation by the oral direct thrombin inhibitor ximelagatran in shed blood from healthy male subjects.
Troy C Sarich, Ulf G Eriksson, Christer Mattsson, Michael Wolzt, Lars Frison, Gunnar Fager

Thromb Haemost· February 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis